Literature DB >> 25531930

Advances in ophthalmic drug delivery.

Peter W J Morrison1, Vitaliy V Khutoryanskiy.   

Abstract

Various strategies for ocular drug delivery are considered; from basic formulation techniques for improving availability of drugs; viscosity enhancers and mucoadhesives aid drug retention and penetration enhancers promote drug transport into the eye. The use of drug-loaded contact lenses and ocular inserts allows drugs to be better placed where they are needed for more direct delivery. Developments in ocular implants gives a means to overcome the physical barriers that traditionally prevented effective treatment. Implant technologies are under development allowing long-term drug delivery from a single procedure, these devices allow posterior chamber diseases to be effectively treated. Future developments could bring artificial corneas to eliminate the need for donor tissue and one-off implantable drug depots lasting the patient's lifetime.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531930     DOI: 10.4155/tde.14.75

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  28 in total

Review 1.  Xenobiotic pulmonary exposure and systemic cardiovascular response via neurological links.

Authors:  Phoebe A Stapleton; Alaeddin B Abukabda; Steven L Hardy; Timothy R Nurkiewicz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 2.  In vitro reconstructed 3D corneal tissue models for ocular toxicology and ophthalmic drug development.

Authors:  Yulia Kaluzhny; Mitchell Klausner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-02-05       Impact factor: 2.416

Review 3.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

4.  Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Soumyajit Majumdar
Journal:  Eur J Pharm Biopharm       Date:  2016-10-25       Impact factor: 5.571

5.  Light-responsive biomaterials for ocular drug delivery.

Authors:  Hend A M Abdelmohsen; Nikki A Copeland; John G Hardy
Journal:  Drug Deliv Transl Res       Date:  2022-06-24       Impact factor: 4.617

6.  Safety, efficacy and delivery of multiple nucleoside analogs via drug encapsulated carbon (DECON) based sustained drug release platform.

Authors:  Tejabhiram Yadavalli; Joshua Ames; David Wu; Benjamin Ramirez; Navya Bellamkonda; Deepak Shukla
Journal:  Eur J Pharm Biopharm       Date:  2022-03-21       Impact factor: 5.589

7.  Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation.

Authors:  Seyedeh Negin Kassaee; Mohammad Mehdi Mahboobian
Journal:  Drug Deliv Transl Res       Date:  2021-02-11       Impact factor: 4.617

Review 8.  Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.

Authors:  Felipe M González-Fernández; Annalisa Bianchera; Paolo Gasco; Sara Nicoli; Silvia Pescina
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

Review 9.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

Review 10.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.